Table 4.
Subgroup | N | Mean LVM (g) ± SD | Difference in LVM (g) per 20% greater dietary phosphorus (95% CI)† |
---|---|---|---|
Overall cohort | 4494 | 145 ± 39 | 1.06 (0.50, 1.62) |
Men | 2167 | 169 ± 37 | 0.59 (−0.49, 1.67) |
Women | 2327 | 124 ± 27 | 1.24 (0.58, 1.89) |
Pre-menopausal women | 355 | 122 ± 25 | 0.42 (−1.27, 2.11) |
Post-menopausal women | 1,878 | 124 ± 28 | 1.38 (0.65, 2.12) |
Age 45–64 years | 2467 | 147 ± 39 | 0.97 (0.27, 1.67) |
Age 65–84 years | 1847 | 142 ± 39 | 1.22 (0.29, 2.16) |
White | 1820 | 144 ± 38 | 0.89 (0.08, 1.71) |
Black | 1074 | 158 ± 41 | 0.76 (−0.70, 2.23) |
Asian | 623 | 124 ± 31 | 0.98 (−0.18, 2.15) |
Hispanic | 977 | 148 ± 38 | 1.55 (0.34, 2.76) |
Hypertension1 | 2050 | 153 ± 41 | 1.05 (0.12, 1.98) |
No Hypertension1 | 2442 | 138 ± 36 | 0.91 (0.22, 1.59) |
Chronic kidney disease | 421 | 142 ± 40 | 2.01 (0.24, 3.78) |
No chronic kidney disease | 4061 | 146 ± 39 | 0.99 (0.40, 1.99) |
Except for the covariate representing the subgroup of interest, all models weighed and combined by sex and adjusted for age, race, height, weight and weight0.5, total dietary calories, dietary sodium, smoking, alcohol use, education, moderate-vigorous physical activity, diabetes status, systolic blood pressure, anti-hypertensive medication use, urinary albumin to creatinine ratio, C-reactive protein, and estimated glomerular filtration rate.
Hypertension models exclude adjustment for systolic blood pressure and anti-hypertensive medication use.